These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32949229)

  • 61. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.
    Akhtar RS; Licata JP; Luk KC; Shaw LM; Trojanowski JQ; Lee VM
    J Neurochem; 2018 Jun; 145(6):489-503. PubMed ID: 29500813
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
    BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
    [TBL] [Abstract][Full Text] [Related]  

  • 63. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.
    Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J
    Acta Neuropathol; 2013 Nov; 126(5):683-97. PubMed ID: 23812319
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
    Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vivo assessment of Lewy body and beta-amyloid copathologies in idiopathic normal pressure hydrocephalus: prevalence and associations with clinical features and surgery outcome.
    Giannini G; Baiardi S; Dellavalle S; Zenesini C; Cevoli S; Danner N; Jyrkkänen HK; Rossi M; Polischi B; Quadalti C; Stefanini C; Cortelli P; Milletti D; Herukka SK; Palandri G; Leinonen V; Parchi P
    Fluids Barriers CNS; 2022 Sep; 19(1):71. PubMed ID: 36071460
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CSF biomarkers and clinical progression of Parkinson disease.
    Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
    Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort.
    Law LL; Sprecher KE; Dougherty RJ; Edwards DF; Koscik RL; Gallagher CL; Carlsson CM; Zetterberg H; Blennow K; Asthana S; Sager MA; Hermann BP; Johnson SC; Cook DB; Bendlin BB; Okonkwo OC
    J Alzheimers Dis; 2019; 69(1):111-121. PubMed ID: 30958346
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults.
    Sprecher KE; Koscik RL; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Sager MA; Asthana S; Johnson SC; Benca RM; Bendlin BB
    Neurology; 2017 Aug; 89(5):445-453. PubMed ID: 28679595
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.
    Nielsen HM; Hall S; Surova Y; Nägga K; Nilsson C; Londos E; Minthon L; Hansson O; Wennström M
    J Alzheimers Dis; 2014; 40(2):343-50. PubMed ID: 24448788
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
    J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults.
    Liu W; Li W; Liu Z; Li Y; Wang X; Guo M; Wang S; Wang S; Li Y; Jia J
    Alzheimers Res Ther; 2024 May; 16(1):103. PubMed ID: 38725083
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases.
    Schaeffer MJ; Callahan BL;
    J Alzheimers Dis; 2019; 70(3):877-887. PubMed ID: 31282412
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Left Ventricular Ejection Fraction and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Normal Older Adults: The CABLE Study.
    Zheng YM; Zhao YY; Zhang T; Hou XH; Bi YL; Ma YH; Xu W; Shen XN; Dong Q; Tan L; Yu JT
    J Alzheimers Dis; 2021; 81(2):743-750. PubMed ID: 33814430
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association of cerebrospinal fluid α-synuclein with total and phospho-tau
    Vergallo A; Bun RS; Toschi N; Baldacci F; Zetterberg H; Blennow K; Cavedo E; Lamari F; Habert MO; Dubois B; Floris R; Garaci F; Lista S; Hampel H; ;
    Alzheimers Dement; 2018 Dec; 14(12):1623-1631. PubMed ID: 30055132
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 78. VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies.
    van Steenoven I; Noli B; Cocco C; Ferri GL; Oeckl P; Otto M; Koel-Simmelink MJA; Bridel C; van der Flier WM; Lemstra AW; Teunissen CE
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547145
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
    J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.